Which thiazide to choose as add-on therapy for hypertension?

Integrated Blood Pressure Control

Volumn 7, Issue 1, 2014, Pages 35-47

  Barrios, Vivencio ^a   Escobar, Carlos ^b  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Blood pressure control; Chlorthalidone; Combined therapy; Hydrochlorothiazide; Indapamide; Thiazide like diuretics

Indexed keywords

AMILORIDE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; AZILSARTAN; AZILSARTAN MEDOXOMIL; AZILSARTAN MEDOXOMIL PLUS CHLORTALIDONE; CANDESARTAN; CAPTOPRIL PLUS HYDROCHLOROTHIAZIDE; CHLORTALIDONE; DELAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; HYDROCHLOROTHIAZIDE PLUS OLMESARTAN; INDAPAMIDE; INDAPAMIDE PLUS PERINDOPRIL; LOSARTAN; OLMESARTAN; PERINDOPRIL; PLACEBO; VALSARTAN;

ADD ON THERAPY; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; HEART FAILURE; HEART PROTECTION; HUMAN; HYPERTENSION; MONOTHERAPY; NONHUMAN; REVIEW; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT;

EID: 84905246629     PISSN: None     EISSN: 11787104     Source Type: Book Series    
DOI: 10.2147/IBPC.S40248     Document Type: Review

References (98)

1. Barrios V, Escobar C. Is a new crash coming? J Hypertens Open Access. 2012; 1: e105.
2. Lawes CM, Vander Hoorn S, Rodgers A; International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet. 2008; 371(9623): 1513-1518.
3. Pereira M, Lunet N, Azevedo A, Barros H. Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries. J Hypertens. 2009; 27(5): 963-975.
4. Stephens MM, Fox BA, Maxwell L. Therapeutic options for the treatment of hypertension in children and adolescents. Clin Med Insights Circ Respir Pulm Med. 2012; 6: 13-25.
5. Wijeysundera HC, Machado M, Farahati F, et al. Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994-2005. JAMA. 2010; 303(18): 1841-1847.
6. Flores-Mateo G, Grau M, O'Flaherty M, et al. Analyzing the coronary heart disease mortality decline in a Mediterranean population: Spain 1988-2005. Rev Esp Cardiol. 2011; 64(11): 988-996.
7. Mancia G, Messerli F, Bakris G, et al. Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension. 2007; 50(2): 299-305.
8. Egan BM, Zhao Y, Axon RN. US Trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA. 2010; 303(20): 2043-2050.
9. McAlister FA, Wilkins K, Joffres M, et al. Changes in the rates of awareness, treatment and control of hypertension in Canada over the past two decades. CMAJ. 2011; 183(9): 1007-1013.
10. Fasce E, Campos I, Ibáñez P, et al. Trends in prevalence, awareness, treatment and control of hypertension in urban communities in Chile. J Hypertens. 2007; 25(9): 1807-1811.
11. Cífková R, Skodová Z, Bruthans J, et al. Longitudinal trends in cardiovascular mortality and blood pressure levels, prevalence, awareness, treatment, and control of hypertension in the Czech population from 1985 to2007/2008. J Hypertens. 2010; 28(11): 2196-2203.
12. Llisterri JL, Rodriguez-Roca GC, Escobar C, et al; on behalf of the Working Group of Arterial Hypertension of the Spanish Society of Primary Care Physicians (Group HTASEMERGEN); and the PRESCAP 2010 investigators. Treatment and blood pressure control in Spain during 2002-2010. J Hypertens. 2012; 30(12): 2425-2431.
13. Barrios V, Escobar C. Letter from Barrios and Escobar regarding article, "trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health and Nutrition Examination Survey, 2001 to2010". Circulation. 2013; 127(24): e859.
14. Escobar C, Echarri R, Barrios V. Emerging drug combinations to optimize renovascular protection and blood pressure goals. Int J Nephrol Renovasc Dis. 2012; 5: 69-80.
15. Escobar C, Barrios V. Combined therapy in the treatment of hypertension. Fundam Clin Pharmacol. 2010; 24(1): 3-8.
16. James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC8). JAMA. 2014; 311(5): 507-520.
17. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013; 34(28): 2159-2219.
18. Motwani JG. Combining renin-angiotensin-aldosterone system blockade with diuretic therapy for treatment of hypertension. J Renin Angiotensin Aldosterone Syst. 2002; 3(2): 72-78.
19. Barrios V, Escobar C. Olmesartan medoxomil plus hydrochlorothiazide for treating hypertension. Expert Opin Pharmacother. 2008; 9(1): 129-136.
20. Barrios V, Escobar C. Azilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker? Expert Opin Pharmacother. 2013; 14(16): 2249-2261.
21. Barrios V, Escobar C. Complementary mechanisms of action and rationale for the fixed combination of perindopril and indapamide in treating hypertension-update on clinical utility. Integr Blood Press Control. 2010; 3: 11-19.
22. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension. 2004; 43(1): 4-9.
23. Giudicelli JF, Richer C, Mattei A. Pharmacokinetics and biological effects of captopril and hydrochlorothiazide after acute and chronic administration either alone or in combination in hypertensive patients. Br J Clin Pharmacol. 1987; 23 Suppl1: 51S-63S.
24. Weir SJ, Dimmitt DC, Lanman RC, Morrill MB, Geising DH. Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. Biopharm Drug Dispos. 1998; 19(6): 365-371.
25. Allen JH, McKenney JM, Stratton MA, Link K. Antihypertensive effect of hydrochlorothiazide administered once or twice daily. Clin Pharm. 1982; 1(3): 239-243.
26. Kohvakka A, Salo H, Gordin A, Eisalo A. Antihypertensive and biochemical effects of different doses of hydrochlorothiazide alone or in combination with triamterene. Acta Med Scand. 1986; 219(4): 381-386.
27. Cushman WC, Khatri I, Materson BJ, et al. Treatment of hypertension in the elderly, III: response of isolated systolic hypertension to various doses of hydrochlorothiazide: results of a Department of Veterans Affairs cooperative study. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Arch Intern Med. 1991; 151(10): 1954-1960.
28. Jounela AJ, Lilja M, Lumme J, et al. Relation between low dose of hydrochlorothiazide, antihypertensive effect and adverse effects. Blood Press. 1994; 3(4): 231-235.
29. Materson BJ, Oster JR, Michael UF, et al. Dose response to chlorthalidone in patients with mild hypertension: efficacy of a lower dose. Clin Pharmacol Ther. 1978; 24(2): 192-198.
30. Morledge JH, Ettinger B, Aranda J, et al. Isolated systolic hypertension in the elderly: a placebo controlled, dose-response evaluation of chlorthalidone. J Am Geriatr Soc. 1986; 34(3): 199-206.
31. Schiavi P, Jochemsen R, Guez D. Pharmacokinetics of sustained and immediate release formulations of indapamide after single and repeated oral administration in healthy volunteers. Fundam Clin Pharmacol. 2000; 14(2): 139-146.
32. Robinson DM, Wellington K. Indapamide sustained release: a review of its use in the treatment of hypertension. Drugs. 2006; 66(2): 257-271.
33. Guerrero P, Fuchs FD, Moreira LM, et al. Blood pressure-lowering efficacy of amiloride versus enalapril as add-on drugs in patients with uncontrolled blood pressure receiving hydrochlorothiazide. Clin Exp Hypertens. 2008; 30(7): 553-564.
34. Neutel JM, Saunders E, Bakris GL, et al. The eff icacy and safety of low-and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich). 2005; 7(10): 578-586.
35. Karlson BW, Zetterstrand S, Olofsson B, Elmfeldt D. A dose-response analysis of candesartan-hydrochlorothiazide combination therapy in patients with hypertension. Blood Press. 2009; 18(3): 149-156.
36. Edes I, Burgess L, Parow W, et al. Combination therapy with candesartan cilexetil32 mg and hydrochlorothiazide25 mg provides the full additive antihypertensive effect of the components: a randomized, double-blind, parallel-group study in primary care. Clin Drug Investig. 2009; 29(5): 293-304.
37. Bönner G, Calder B, Dzyak G, et al. Antihypertensive efficacy and tolerability of candesartan-hydrochlorothiazide32/12. 5 mg and 32/25 mg in patients not optimally controlled with candesartan monotherapy. Blood Press Suppl. 2008; 2: 22-30.
38. Barrios V, Escobar C. Candesartan in the treatment of hypertension: what have we learnt in the last decade? Expert Opin Drug Saf. 2011; 10(6): 957-968.
39. Barrios V, Boccanelli A, Ewald S, et al. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST study. Clin Drug Investig. 2007; 27(8): 545-558.
40. Sica D, Bakris GL, White WB, et al. Blood pressure lowering efficacy of the fixed dose combination of azilsartan and chlorthalidone: a factorial study. J Clin Hypertens (Greenwich). 2012; 14(5): 284-292.
41. Roush GC, Buddharaju V, Ernst ME, Holford TR. Chlorthalidone: mechanisms of action and effect on cardiovascular events. Curr Hypertens Rep. 2013; 15(5): 514-521.
42. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991; 265(24): 3255-3264.
43. Curb JD, Pressel SL, Cutler JA, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA. 1996; 276(23): 1886-1892.
44. Kostis JB, Davis BR, Cutler J, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA. 1997; 278(3): 212-216.
45. Kostis JB, Cabrera J, Cheng JQ, et al. Association between chlorthalidone treatment of systolic hypertension and long-term survival. JAMA. 2011; 306(23): 2588-2593.
46. Oparil S, Davis BR, Cushman WC, et al; ALLHAT Collaborative Research Group. Mortality and morbidity during and after Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: results by sex. Hypertension. 2013; 61(5): 977-986.
47. Rahman M, Pressel S, Davis BR, et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005; 165(8): 936-946.
48. Savage PJ, Pressel SL, Curb JD, et al. Influence of long-term, lowdose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Arch Intern Med. 1998; 158: 741-751.
49. Dorsch MP, Gillespie BW, Erickson SR, Bleske BE, Weder AB. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension. 2011; 57(4): 689-694.
50. Basile JN, Bloch MJ. Determining the relative antihypertensive potency and relative cardiovascular risk reduction associated with different thiazide and thiazide-type diuretics. J Clin Hypertens (Greenwich). 2013; 15(6): 359-361.
51. Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006; 47(3): 352-358.
52. Bakris GL, Sica D, White WB, et al. Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. Am J Med. 2012; 125(12): 1229.
53. Peterzan MA, Hardy R, Chaturvedi N, Hughes AD. Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. Hypertension. 2012; 59(6): 1104-1109.
54. Ernst ME, Carter BL, Zheng S, Grimm RH Jr. Meta-analysis of doseresponse characteristics of hydrochlorothiazide and chlorthalidone: effects on systolic blood pressure and potassium. Am J Hypertens. 2010; 23(4): 440-446.
55. Matthews KA, Brenner MJ, Brenner AC. Evaluation of the efficacy and safety of a hydrochlorothiazide to chlorthalidone medication change in veterans with hypertension. Clin Ther. 2013; 35(9): 1423-1430.
56. Kwon BJ, Jang SW, Choi KY, et al. Comparison of the efficacy between hydrochlorothiazide and chlorthalidone on central aortic pressure when added on to candesartan in treatment-naïve patients of hypertension. Hypertens Res. 2013; 36(1): 79-84.
57. Ernst ME, Neaton JD, Grimm RH Jr, et al; Multiple Risk Factor Intervention Trial Research Group. Long-term effects of chlorthalidone versus hydrochlorothiazide on electrocardiographic left ventricular hypertrophy in the Multiple Risk Factor Intervention Trial. Hypertension. 2011; 58(6): 1001-1007.
58. Woodman R, Brown C, Lockette W. Chlorthalidone decreases platelet aggregation and vascular permeability and promotes angiogenesis. Hypertension. 2010; 56(3): 463-470.
59. Roush GC, Holford TR, Guddati AK. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension. 2012; 59(6): 1110-1117.
60. Dhalla IA, Gomes T, Yao Z, Nagge J, et al. Chlorthalidone versus hydrochlorothiazide for the treatment of hypertension in older adults: a population-based cohort study. Ann Intern Med. 2013; 158(6): 447-455.
61. Roush GC, Buddharaju V, Ernst ME. Is chlorthalidone better than hydrochlorothiazide in reducing cardiovascular events in hypertensives? Curr Opin Cardiol. 2013; 28(4): 426-432.
62. National Institute for Health and Clinical Excellence. Hypertension. The clinical management of primary hypertension in adults. Aug2011. Available from: http://www. nice. org. uk/guidance/CG127. Accessed April3, 2014.
63. Mourad JJ, Waeber B, Zannad F, M, Duru G, Andréjak M; Investigators of the STRATHE Trial. Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach. J Hypertens. 2004; 22(12): 2379-2386.
64. Farsang C; Picasso Investigators. Blood pressure and metabolic efficacy of fixed-dose combination of perindopril and indapamide in everyday practice. Blood Press. 2013; 22 Suppl1: 3-10.
65. Netchessova TA, Shepelkevich AP, Gorbat TV; on behalf of the NIKA Study Group. Efficacy of single-pill perindopril/indapamide in patients with hypertension and type2diabetes. High Blood Press Cardiovasc Prev. 2014; 21(1): 63-69.
66. Pella D. Efficacy and safety of treatment of hypertensive patients with fixed combination perindopril/indapamide up to10/2. 5 mg: results of the FALCO FORTE programme. High Blood Press Cardiovasc Prev. 2011; 18(3): 107-113.
67. Kang S, Wu YF, An N, Ren M. A systematic review and meta-analysis of the efficacy and safety of a fixed, low-dose perindopril-indapamide combination as first-line treatment of hypertension. Clin Ther. 2004; 26(2): 257-270.
68. ADVANCE Echocardiography Substudy Investigators; ADVANCE Collaborative Group. Effects of perindopril-indapamide on left ventricular diastolic function and mass in patients with type2diabetes: the ADVANCE Echocardiography Substudy. J Hypertens. 2011; 29(7): 1439-1447.
69. Barrios V, Escobar C, Divison JA, Medialdea F. Low-dose fixed combination of perindopril plus indapamide in the diabetic hypertensive population. Expert Rev Cardiovasc Ther. 2008; 6(8): 1063-1069.
70. Protasov KV, Sinkevich DA, Reshina IV, Zhizhko NV, Logovikova SI, Golubeva LV. [Vascular effects of perindopril arginine and indapamide fixed combination in patients with arterial hypertension]. Kardiologiia. 2012; 52(9): 8-14. Russian.
71. Neglia D, Fommei E, Varela-Carver A, et al. Perindopril and indapamide reverse coronary microvascular remodelling and improve flow in arterial hypertension. J Hypertens. 2011; 29: 364-372.
72. Hlavačková L, Vranková S, Janega P, Pecháňová O, Babál P. The effect of indapamide on development of myocardial hypertrophy and fibrosis in L-NAME-induced hypertension in rat. Physiol Res. 2011; 60: 845-852.
73. PROGRESS Collaborative Group. Randomised trial of a perindoprilbased blood-pressure-lowering regimen among6, 105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001; 358(9287): 1033-1041.
74. Patel A; ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type2diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007; 370(9590): 829-840.
75. Ninomiya T, Zoungas S, Neal B, et al; ADVANCE Collaborative Group. Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial. J Hypertens. 2010; 28(6): 1141-1149.
76. Heerspink HJ, Ninomiya T, Perkovic V, et al; ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide in patients with type2diabetes and chronic kidney disease. Eur Heart J. 2010; 31(23): 2888-2896.
77. Beckett NS, Peters R, Fletcher AE, et al. HYVET Study Group. Treatment of hypertension in patients80 years of age or older. N Engl J Med. 2008; 358(18): 1887-1898.
78. Beckett N, Peters R, Tuomilehto J, et al; HYVET Study Group. Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to Hypertension in the Very Elderly randomised controlled trial. BMJ. 2011; 344: d7541.
79. González-Juanatey JR, Cordero A. Benefits of delapril in hypertensive patients along the cardiovascular continuum. Expert Rev Cardiovasc Ther. 2013; 11(3): 271-281.
80. Rosei EA, Rizzoni D; DIMS II (Delapril-Indapamide Multicenter Study II). Evaluation of the efficacy and tolerability of the combination delapril plus indapamide in the treatment of mild to moderate essential hypertension: a randomised, multicentre, controlled study. J Hum Hypertens. 2003; 17(2): 139-146.
81. Acanfora D, Lowenthal DT, Furgi G, et al. Effects of delapril in combination with indapamide on blood pressure and left ventricular mass in elderly hypertensive patients. Am J Ther. 1998; 5(1): 17-23.
82. Acanfora D, Lowenthal DT, Furgi G, et al. The effects of delapril in combination with indapamide on glomerular filtration rate in elderly hypertensive patients. Am J Ther. 1997; 4(11-12): 405-408.
83. Leonetti G, Emeriau JP, Knauf H, Pujadas JO, Calvo-Gomez C, Abate G; European Study Investigators. Evaluation of long-term efficacy and acceptability of indapamide SR in elderly hypertensive patients. Curr Med Res Opin. 2005; 21(1): 37-46.
84. Nedogoda SV, Marchenko IV, Chaliabi TA, Tsoma VV, Brel UA, Prokhorova EA. [Comparative efficacy of fixed dose combinations of perindopril with indapamide and captopril with hydrochlorothiazide in patients with high risk hypertension]. Kardiologiia. 2005; 45(11): 24-26. Russian.
85. Karpov IA. [The FORTISSIMO program: advantages of fixed full dose combination of perindopril arginine and indapamide in the treatment of poorly controlled arterial hypertension]. Kardiologiia. 2013; 53(3): 37-43. Russian.
86. Cremonesi G, Cavalieri L, Cikes I, et al. Fixed combinations of delapril plus indapamide vs fosinopril plus hydrochlorothiazide in mild to moderate essential hypertension. Adv Ther. 2002; 19(3): 129-137.
87. Circelli M, Nicolini G, Egan CG, Cremonesi G. Eff icacy and safety of delapril/indapamide compared to different ACE-inhibitor/hydrochlorothiazide combinations: a meta-analysis. Int J Gen Med. 2012; 5: 725-734.
88. Semenkin AA, Zhivilova LA, Golevtsova ZS, et al. [Comparative assessment of hypotensive, metabolic, and endothelial effects of indapamide-retard and hydrochlorothiazide in patients with essential hypertension]. Kardiologiia. 2006; 46(5): 35-39. Russian.
89. Islam MZ, Rahman MS. Comparative study of hydrochlorothiazide and indapamide on the anti-atherogenic potential of losartan in cholesterol fed rat. Bangladesh Med Res Counc Bull. 2010; 36(1): 14-19.
90. Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003; 289(19): 2560-2572.
91. Carter BL. Guidelines for use of diuretics: a view from a member of JNC7. J Clin Hypertens (Greenwich). 2012; 14(5): 273-276.
92. Kountz DS, Goldman A, Mikhail J, Ezer M. Chlorthalidone: the forgotten diuretic. Postgrad Med. 2012; 124(1): 60-66.
93. Waeber B, Rotaru C, Feihl F. Position of indapamide, a diuretic with vasorelaxant activities, in antihypertensive therapy. Expert Opin Pharmacother. 2012; 13(10): 1515-1526.
94. Padilla MC, Armas-Hernández MJ, Hernández RH, Israili ZH, Valasco M. Update of diuretics in the treatment of hypertension. Am J Ther. 2007; 14(2): 154-160.
95. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341(10): 709-717.
96. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003; 348(14): 1309-1321.
97. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011; 364(1): 11-21.
98. Ernst ME, Lund BC. Renewed interest in chlorthalidone: evidence from the Veterans Health Administration. J Clin Hypertens (Greenwich). 2010; 12(12): 927-934.